{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:33:30Z","timestamp":1793892810881,"version":"4.8.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China,China","doi-asserted-by":"crossref","award":["82174169"],"award-info":[{"award-number":["82174169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combination therapy is rapidly becoming the cornerstone of hepatocellular carcinoma (HCC) treatment. Immune checkpoint inhibitors (ICIs) have emerged as a central strategy in systemic therapy, yet their efficacy as monotherapies remains limited. Consequently, combinatorial approaches, such as ICIs-Tyrosine kinase inhibitors (TKIs), ICIs-chemotherapy, and dual ICI regimens, are gaining momentum. While\u00a0clinical trials have established efficacy benchmarks, mechanistic insights remain scarce, partly due to the limitations of current preclinical models in mimicking the complex tumor microenvironment (TME). Given the substantial heterogeneity of HCC, spanning genetic, transcriptomic, and immunologic dimensions, treatment outcomes vary widely. Additional factors such as gut microbiota and epigenetic modifications further influence therapeutic response and resistance. Although PD-1, PD-L1, and CTLA-4 inhibitors are widely used, unresponsiveness is common. Novel targets such as\u00a0LAG-3, TIM-3, TIGIT, and VISTA, as well as strategies to reprogram fibrotic and immunosuppressive TME, are under active investigation. Ultimately, translating basic insights into personalized therapy will depend on predictive biomarkers and integrated analyses that account for the complex interactions among tumor cells, the immune system, and the TME. This review synthesizes current knowledge and cellular mechanisms underpinning combination therapies, highlights therapeutic synergies, and discusses emerging directions for stratified treatment in HCC.\u00a0<\/jats:p>","DOI":"10.1186\/s13045-025-01739-6","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:21:35Z","timestamp":1758882095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy"],"prefix":"10.1186","volume":"18","author":[{"given":"Suoyi","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Shan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1739_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345\u201362.","journal-title":"Lancet"},{"issue":"5","key":"1739_CR2","first-page":"e474","volume":"2024","author":"X Luo","year":"2020","unstructured":"Luo X, He X, Zhang X, Zhao X, Zhang Y, Shi Y, et al. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm. 2020;2024(5):e474.","journal-title":"MedComm"},{"key":"1739_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"1739_CR4","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502.","journal-title":"Lancet"},{"key":"1739_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940\u201352.","journal-title":"Lancet Oncol"},{"key":"1739_CR6","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6:e204564.","journal-title":"JAMA Oncol"},{"key":"1739_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10:35.","journal-title":"Signal Transduct Target Ther"},{"key":"1739_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450\u201362.","journal-title":"N Engl J Med"},{"key":"1739_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","volume":"13","author":"Y Yin","year":"2024","unstructured":"Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024;13:72.","journal-title":"Exp Hematol Oncol"},{"key":"1739_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","volume":"20","author":"C Viallard","year":"2017","unstructured":"Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20:409\u201326.","journal-title":"Angiogenesis"},{"key":"1739_CR11","doi-asserted-by":"publisher","first-page":"117343","DOI":"10.1016\/j.biopha.2024.117343","volume":"179","author":"Q Deng","year":"2024","unstructured":"Deng Q, Huang Y, Zeng J, Li X, Zheng X, Guo L, et al. Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): structure-activity relationships, pharmacological activities, and the clinical trials. Biomed Pharmacother. 2024;179:117343.","journal-title":"Biomed Pharmacother"},{"key":"1739_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","volume":"43","author":"H Zhu","year":"2020","unstructured":"Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol (Dordr). 2020;43:1203\u201314.","journal-title":"Cell Oncol (Dordr)"},{"key":"1739_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jhep.2011.07.031","volume":"56","author":"U Asghar","year":"2012","unstructured":"Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol. 2012;56:686\u201395.","journal-title":"J Hepatol"},{"key":"1739_CR14","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1739_CR15","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960\u201370.","journal-title":"J Clin Oncol"},{"key":"1739_CR16","doi-asserted-by":"publisher","first-page":"107161","DOI":"10.1016\/j.phrs.2024.107161","volume":"203","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Tan H, Wang J, Zhuang H, Zhao H, Lu X. Molecular insight into T cell exhaustion in hepatocellular carcinoma. Pharmacol Res. 2024;203:107161.","journal-title":"Pharmacol Res"},{"key":"1739_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69:301\u201318.","journal-title":"Annu Rev Med"},{"key":"1739_CR18","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, et al. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20:724\u201335.","journal-title":"Nat Immunol"},{"key":"1739_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","volume":"23","author":"A Zhang","year":"2024","unstructured":"Zhang A, Fan T, Liu Y, Yu G, Li C, Jiang Z. Regulatory t cells in immune checkpoint blockade antitumor therapy. Mol Cancer. 2024;23:251.","journal-title":"Mol Cancer"},{"key":"1739_CR20","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257\u201365.","journal-title":"J Exp Med"},{"key":"1739_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12072-019-10003-2","volume":"14","author":"J Liao","year":"2020","unstructured":"Liao J, Zeng DN, Li JZ, Hua QM, Xiao Z, He C, et al. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatol Int. 2020;14:80\u201395.","journal-title":"Hepatol Int"},{"key":"1739_CR22","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.18632\/oncotarget.12278","volume":"8","author":"CR Millrud","year":"2017","unstructured":"Millrud CR, Bergenfelz C, Leandersson K. On the origin of myeloid-derived suppressor cells. Oncotarget. 2017;8:3649\u201365.","journal-title":"Oncotarget"},{"key":"1739_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12964-025-02170-7","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu X, Kang X, Kang H, Yan H. The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities. Cell Commun Signal. 2025;23:155.","journal-title":"Cell Commun Signal"},{"key":"1739_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41419-024-06888-z","volume":"15","author":"D Li","year":"2024","unstructured":"Li D, Zhang T, Guo Y, Bi C, Liu M, Wang G. Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma. Cell Death Dis. 2024;15:498.","journal-title":"Cell Death Dis"},{"issue":"829\u2013845","key":"1739_CR25","first-page":"e820","volume":"179","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, et al. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell. 2019;179(829\u2013845):e820.","journal-title":"Cell"},{"key":"1739_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/2326-6066.CIR-16-0011","volume":"4","author":"E Pure","year":"2016","unstructured":"Pure E, Lo A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors? Cancer Immunol Res. 2016;4:269\u201378.","journal-title":"Cancer Immunol Res"},{"key":"1739_CR27","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.7150\/thno.28742","volume":"8","author":"LJ Ma","year":"2018","unstructured":"Ma LJ, Feng FL, Dong LQ, Zhang Z, Duan M, Liu LZ, et al. Clinical significance of PD-1\/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics. 2018;8:5690\u2013702.","journal-title":"Theranostics"},{"key":"1739_CR28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","volume":"15","author":"Q Gao","year":"2009","unstructured":"Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15:971\u20139.","journal-title":"Clin Cancer Res"},{"key":"1739_CR29","doi-asserted-by":"publisher","first-page":"861525","DOI":"10.3389\/fimmu.2022.861525","volume":"13","author":"Y Guo","year":"2022","unstructured":"Guo Y, Yang J, Ren K, Tian X, Gao H, Tian X, et al. The heterogeneity of immune cell infiltration landscape and its immunotherapeutic implications in hepatocellular carcinoma. Front Immunol. 2022;13:861525.","journal-title":"Front Immunol"},{"key":"1739_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.","journal-title":"J Immunother Cancer"},{"key":"1739_CR31","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1084\/jem.20161462","volume":"213","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213:2835\u201340.","journal-title":"J Exp Med"},{"key":"1739_CR32","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362:k3529.","journal-title":"BMJ"},{"key":"1739_CR33","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","volume":"26","author":"L Fong","year":"2008","unstructured":"Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275\u201383.","journal-title":"J Clin Oncol"},{"key":"1739_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58\u201367.","journal-title":"Blood"},{"key":"1739_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory t cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"1739_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s13046-019-1396-4","volume":"38","author":"Y Fu","year":"2019","unstructured":"Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:396.","journal-title":"J Exp Clin Cancer Res"},{"key":"1739_CR37","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/cas.15719","volume":"114","author":"Z Mei","year":"2023","unstructured":"Mei Z, Gao X, Pan C, Wu Q, Wang S, Qian J, et al. Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1(+) CD8(+) T cells in HCC via blocking VEGFR2. Cancer Sci. 2023;114:1284\u201396.","journal-title":"Cancer Sci"},{"key":"1739_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-018-0403-1","volume":"6","author":"Y Tada","year":"2018","unstructured":"Tada Y, Togashi Y, Kotani D, Kuwata T, Sato E, Kawazoe A, et al. Targeting VEGFR2 with ramucirumab strongly impacts effector\/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment. J Immunother Cancer. 2018;6:106.","journal-title":"J Immunother Cancer"},{"key":"1739_CR39","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.1002\/cam4.4312","volume":"10","author":"J Zhu","year":"2021","unstructured":"Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, et al. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med. 2021;10:7977\u201387.","journal-title":"Cancer Med"},{"key":"1739_CR40","first-page":"2963","volume":"5","author":"DI Gabrilovich","year":"1999","unstructured":"Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963\u201370.","journal-title":"Clin Cancer Res"},{"key":"1739_CR41","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang J, Yan J, Liu B. Targeting VEGF\/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978.","journal-title":"Front Immunol"},{"key":"1739_CR42","doi-asserted-by":"publisher","first-page":"102221","DOI":"10.1016\/j.ctrv.2021.102221","volume":"98","author":"AB El-Khoueiry","year":"2021","unstructured":"El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. Cabozantinib: an evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021;98:102221.","journal-title":"Cancer Treat Rev"},{"key":"1739_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/gut.48.1.87","volume":"48","author":"Z von Marschall","year":"2001","unstructured":"von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut. 2001;48:87\u201396.","journal-title":"Gut"},{"key":"1739_CR44","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109:17561\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1739_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60.","journal-title":"Mol Cancer"},{"key":"1739_CR46","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.4161\/cbt.22002","volume":"13","author":"C Fung","year":"2012","unstructured":"Fung C, Chen X, Grandis JR, Duvvuri U. EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer Biol Ther. 2012;13:1417\u201324.","journal-title":"Cancer Biol Ther"},{"key":"1739_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.immuni.2013.07.017","volume":"39","author":"Y Ma","year":"2013","unstructured":"Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity. 2013;39:211\u201327.","journal-title":"Immunity"},{"key":"1739_CR48","doi-asserted-by":"publisher","unstructured":"Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, et al. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-001435.","DOI":"10.1136\/jitc-2020-001435"},{"key":"1739_CR49","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ijrobp.2024.09.024","volume":"121","author":"H Sheng","year":"2025","unstructured":"Sheng H, Luo Y, Zhong L, Wang Z, Sun Z, Gao X, et al. Antiangiogenic treatment facilitates the abscopal effect of radiation therapy combined with anti-PD-1 in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2025;121:534\u201346.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1739_CR50","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology. 2021;74:2544\u201360.","journal-title":"Hepatology"},{"key":"1739_CR51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30:187\u2013200.","journal-title":"J Am Soc Nephrol"},{"key":"1739_CR52","doi-asserted-by":"publisher","unstructured":"Gabbia D, De Martin S. Tumor mutational burden for predicting prognosis and therapy outcome of hepatocellular carcinoma. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24043441.","DOI":"10.3390\/ijms24043441"},{"key":"1739_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","volume":"12","author":"N Zhang","year":"2024","unstructured":"Zhang N, Yang X, Piao M, Xun Z, Wang Y, Ning C, et al. Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark Res. 2024;12:26.","journal-title":"Biomark Res"},{"key":"1739_CR54","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","volume":"39","author":"RS Finn","year":"2021","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39:267\u2013267.","journal-title":"J Clin Oncol"},{"key":"1739_CR55","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22:977\u201390.","journal-title":"Lancet Oncol"},{"key":"1739_CR56","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.2023.41.4_suppl.570","volume":"41","author":"Z Ren","year":"2023","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. ORIENT-32: updated characterization of response to sintilimab plus bevacizumab biosimilar (IBI305) vs sorafenib for unresectable hepatocellular carcinoma. J Clin Oncol. 2023;41:570\u2013570.","journal-title":"J Clin Oncol"},{"key":"1739_CR57","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133\u201346.","journal-title":"Lancet"},{"key":"1739_CR58","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","volume":"36","author":"A Vogel","year":"2025","unstructured":"Vogel A, Chan SL, Dawson LA, Kelley RK, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:491\u2013506.","journal-title":"Ann Oncol"},{"key":"1739_CR59","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1399\u2013410.","journal-title":"Lancet Oncol"},{"key":"1739_CR60","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1200\/JCO.22.00972","volume":"41","author":"T Yau","year":"2023","unstructured":"Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, et al. Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the CheckMate 040 trial. J Clin Oncol. 2023;41:1747\u201357.","journal-title":"J Clin Oncol"},{"key":"1739_CR61","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","volume":"14","author":"A Ahmed","year":"2020","unstructured":"Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14:2994\u20133006.","journal-title":"Mol Oncol"},{"key":"1739_CR62","doi-asserted-by":"publisher","first-page":"e2201734","DOI":"10.1002\/advs.202201734","volume":"9","author":"Z Li","year":"2022","unstructured":"Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H, et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci. 2022;9:e2201734.","journal-title":"Adv Sci"},{"key":"1739_CR63","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23:445\u201360.","journal-title":"Nat Rev Drug Discov"},{"key":"1739_CR64","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052\u201361.","journal-title":"Cancer Res"},{"key":"1739_CR65","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","volume":"74","author":"D Alizadeh","year":"2014","unstructured":"Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014;74:104\u201318.","journal-title":"Cancer Res"},{"key":"1739_CR66","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.jhepr.2020.100224","volume":"3","author":"TT Kwong","year":"2021","unstructured":"Kwong TT, Wong CH, Zhou JY, Cheng ASL, Sung JJY, Chan AWH, et al. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. JHEP Rep. 2021;3:100224.","journal-title":"JHEP Rep"},{"key":"1739_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","volume":"42","author":"MT Madondo","year":"2016","unstructured":"Madondo MT, Quinn M, Plebanski M. Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat Rev. 2016;42:3\u20139.","journal-title":"Cancer Treat Rev"},{"key":"1739_CR68","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/ijc.25756","volume":"129","author":"L Rettig","year":"2011","unstructured":"Rettig L, Seidenberg S, Parvanova I, Samaras P, Curioni A, Knuth A, et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer. 2011;129:832\u20138.","journal-title":"Int J Cancer"},{"key":"1739_CR69","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/JHC.S298538","volume":"8","author":"J Mei","year":"2021","unstructured":"Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin WP, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:167\u201376.","journal-title":"J Hepatocell Carcinoma"},{"key":"1739_CR70","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/joim.12708","volume":"283","author":"PS Chowdhury","year":"2018","unstructured":"Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med. 2018;283:110\u201320.","journal-title":"J Intern Med"},{"key":"1739_CR71","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1073\/pnas.1819473116","volume":"116","author":"C Roux","year":"2019","unstructured":"Roux C, Jafari SM, Shinde R, Duncan G, Cescon DW, Silvester J, et al. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proc Natl Acad Sci U S A. 2019;116:4326\u201335.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1739_CR72","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3389\/fphar.2020.00775","volume":"11","author":"L Bao","year":"2020","unstructured":"Bao L, Hao C, Wang J, Wang D, Zhao Y, Li Y, et al. High-dose cyclophosphamide administration orchestrates phenotypic and functional alterations of immature dendritic cells and regulates Th cell polarization. Front Pharmacol. 2020;11:775.","journal-title":"Front Pharmacol"},{"key":"1739_CR73","doi-asserted-by":"publisher","first-page":"820","DOI":"10.4049\/jimmunol.175.2.820","volume":"175","author":"P Correale","year":"2005","unstructured":"Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol. 2005;175:820\u20138.","journal-title":"J Immunol"},{"key":"1739_CR74","doi-asserted-by":"publisher","first-page":"2120676","DOI":"10.1080\/2162402X.2022.2120676","volume":"11","author":"R Barnestein","year":"2022","unstructured":"Barnestein R, Galland L, Kalfeist L, Ghiringhelli F, Ladoire S, Limagne E. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. Oncoimmunology. 2022;11:2120676.","journal-title":"Oncoimmunology"},{"key":"1739_CR75","doi-asserted-by":"publisher","first-page":"217119","DOI":"10.1016\/j.canlet.2024.217119","volume":"598","author":"J Delahousse","year":"2024","unstructured":"Delahousse J, Molina L, Paci A. Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities. Cancer Lett. 2024;598:217119.","journal-title":"Cancer Lett"},{"key":"1739_CR76","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21:15\u201325.","journal-title":"Cell Death Differ"},{"key":"1739_CR77","doi-asserted-by":"publisher","unstructured":"Nandi T, Pradyuth S, Singh AK, Chitkara D, Mittal A. Therapeutic agents for targeting desmoplasia: current status and emerging trends. Drug Discov Today. 2020. https:\/\/doi.org\/10.1016\/j.drudis.2020.09.008.","DOI":"10.1016\/j.drudis.2020.09.008"},{"key":"1739_CR78","doi-asserted-by":"publisher","first-page":"15101","DOI":"10.1073\/pnas.1213353109","volume":"109","author":"T Stylianopoulos","year":"2012","unstructured":"Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A. 2012;109:15101\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1739_CR79","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1111\/cas.13405","volume":"108","author":"JH Kim","year":"2017","unstructured":"Kim JH, Shin BC, Park WS, Lee J, Kuh HJ. Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts. Cancer Sci. 2017;108:2470\u20137.","journal-title":"Cancer Sci"},{"key":"1739_CR80","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11010-020-03861-0","volume":"475","author":"S Li","year":"2020","unstructured":"Li S, Ji J, Zhang Z, Peng Q, Hao L, Guo Y, et al. Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1. Mol Cell Biochem. 2020;475:79\u201391.","journal-title":"Mol Cell Biochem"},{"key":"1739_CR81","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bbi.2019.02.020","volume":"80","author":"AT Sougiannis","year":"2019","unstructured":"Sougiannis AT, VanderVeen BN, Enos RT, Velazquez KT, Bader JE, Carson M, et al. Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. Brain Behav Immun. 2019;80:44\u201355.","journal-title":"Brain Behav Immun"},{"key":"1739_CR82","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971\u20136.","journal-title":"Science"},{"key":"1739_CR83","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17425255.2022.2043849","volume":"18","author":"SJ Leigh","year":"2022","unstructured":"Leigh SJ, Lynch CMK, Bird BRH, Griffin BT, Cryan JF, Clarke G. Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects. Expert Opin Drug Metab Toxicol. 2022;18:5\u201326.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1739_CR84","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","volume":"20","author":"RC Simpson","year":"2023","unstructured":"Simpson RC, Shanahan ER, Scolyer RA, Long GV. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2023;20:697\u2013715.","journal-title":"Nat Rev Clin Oncol"},{"key":"1739_CR85","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jconrel.2021.01.009","volume":"331","author":"M Kwon","year":"2021","unstructured":"Kwon M, Jung H, Nam GH, Kim IS. The right timing, right combination, right sequence, and right delivery for cancer immunotherapy. J Control Release. 2021;331:321\u201334.","journal-title":"J Control Release"},{"key":"1739_CR86","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1200\/JCO.2019.37.15_suppl.4074","volume":"37","author":"S Qin","year":"2019","unstructured":"Qin S, Chen Z, Liu Y, Xiong J, Ren Z, Meng Z, et al. A phase II study of anti\u2013PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. J Clin Oncol. 2019;37:4074\u20134074.","journal-title":"J Clin Oncol"},{"key":"1739_CR87","doi-asserted-by":"publisher","first-page":"944062","DOI":"10.3389\/fimmu.2022.944062","volume":"13","author":"D Li","year":"2022","unstructured":"Li D, Xu L, Ji J, Bao D, Hu J, Qian Y, et al. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: a prospective, open-label, single-arm, phase II clinical study. Front Immunol. 2022;13:944062.","journal-title":"Front Immunol"},{"key":"1739_CR88","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","volume":"19","author":"PA Ott","year":"2013","unstructured":"Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300\u20139.","journal-title":"Clin Cancer Res"},{"key":"1739_CR89","doi-asserted-by":"publisher","first-page":"643291","DOI":"10.3389\/fimmu.2021.643291","volume":"12","author":"KM van Pul","year":"2021","unstructured":"van Pul KM, Fransen MF, van de Ven R, de Gruijl TD. Immunotherapy goes local: the central role of lymph nodes in driving tumor infiltration and efficacy. Front Immunol. 2021;12:643291.","journal-title":"Front Immunol"},{"key":"1739_CR90","doi-asserted-by":"publisher","first-page":"e0219517","DOI":"10.1371\/journal.pone.0219517","volume":"14","author":"C Hage","year":"2019","unstructured":"Hage C, Hoves S, Ashoff M, Schandl V, Hort S, Rieder N, et al. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. PLoS One. 2019;14:e0219517.","journal-title":"PLoS One"},{"key":"1739_CR91","doi-asserted-by":"publisher","unstructured":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9.","DOI":"10.1016\/S0140-6736(25)00403-9"},{"key":"1739_CR92","doi-asserted-by":"publisher","first-page":"575457","DOI":"10.3389\/fonc.2021.575457","volume":"11","author":"L Zhang","year":"2021","unstructured":"Zhang L, Sun L, Zhou Y, Yu J, Lin Y, Wasan HS, et al. Association of survival and immune-related adverse events with anti-PD-1\/PD-L1 and anti-CTLA-4 inhibitors, alone or their combination for the treatment of cancer: a systematic review and meta-analysis of 13 clinical trials. Front Oncol. 2021;11:575457.","journal-title":"Front Oncol"},{"key":"1739_CR93","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1002\/1521-4141(2002010)32:10<2888::AID-IMMU2888>3.0.CO;2-F","volume":"32","author":"CN Manzotti","year":"2002","unstructured":"Manzotti CN, Tipping H, Perry LC, Mead KI, Blair PJ, Zheng Y, et al. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol. 2002;32:2888\u201396.","journal-title":"Eur J Immunol"},{"key":"1739_CR94","doi-asserted-by":"publisher","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798.","journal-title":"Front Pharmacol"},{"key":"1739_CR95","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest. 2018;128:4654\u201368.","journal-title":"J Clin Invest"},{"key":"1739_CR96","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1073\/pnas.0712237105","volume":"105","author":"FS Hodi","year":"2008","unstructured":"Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105:3005\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1739_CR97","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers. Clin Cancer Res. 2019;25:1233\u20138.","journal-title":"Clin Cancer Res"},{"key":"1739_CR98","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","volume":"26","author":"P Brossart","year":"2020","unstructured":"Brossart P. The role of antigen spreading in the efficacy of immunotherapies. Clin Cancer Res. 2020;26:4442\u20137.","journal-title":"Clin Cancer Res"},{"key":"1739_CR99","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1739_CR100","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1073\/pnas.1016791108","volume":"108","author":"VA Pedicord","year":"2011","unstructured":"Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A. 2011;108:266\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1739_CR101","doi-asserted-by":"publisher","first-page":"e2418985122","DOI":"10.1073\/pnas.2418985122","volume":"122","author":"S Mok","year":"2025","unstructured":"Mok S, Liu H, Agac Cobanoglu D, Anang NAS, Mancuso JJ, Wherry EJ, et al. Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1. Proc Natl Acad Sci U S A. 2025;122:e2418985122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1739_CR102","doi-asserted-by":"publisher","first-page":"1261575","DOI":"10.3389\/fphar.2023.1261575","volume":"14","author":"J Yu","year":"2023","unstructured":"Yu J, Li M, Ren B, Cheng L, Wang X, Ma Z, et al. Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials. Front Pharmacol. 2023;14:1261575.","journal-title":"Front Pharmacol"},{"key":"1739_CR103","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"key":"1739_CR104","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1007\/s10620-016-4042-4","volume":"61","author":"JS Klair","year":"2016","unstructured":"Klair JS, Girotra M, Hutchins LF, Caradine KD, Aduli F, Garcia-Saenz-de-Sicilia M. Ipilimumab-induced gastrointestinal toxicities: a management algorithm. Dig Dis Sci. 2016;61:2132\u20139.","journal-title":"Dig Dis Sci"},{"key":"1739_CR105","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","volume":"40","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40:379\u2013379.","journal-title":"J Clin Oncol"},{"key":"1739_CR106","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","volume":"16","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ma Y, Zang A, Cheng Y, Zhang Y, Wang X, et al. First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors. J Hematol Oncol. 2023;16:50.","journal-title":"J Hematol Oncol"},{"key":"1739_CR107","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","volume":"11","author":"SJ Dovedi","year":"2021","unstructured":"Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, et al. Design and efficacy of a monovalent bispecific PD-1\/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells. Cancer Discov. 2021;11:1100\u201317.","journal-title":"Cancer Discov"},{"key":"1739_CR108","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 2023;24:1134\u201346.","journal-title":"Lancet Oncol"},{"key":"1739_CR109","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024;30:1023\u201334.","journal-title":"Nat Med"},{"key":"1739_CR110","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/jnci\/djr246","volume":"103","author":"RW Humphrey","year":"2011","unstructured":"Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011;103:1222\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"1739_CR111","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","volume":"12","author":"J Prieto","year":"2015","unstructured":"Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681\u2013700.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1739_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071624","author":"A Cigliano","year":"2024","unstructured":"Cigliano A, Liao W, Deiana GA, Rizzo D, Chen X, Calvisi DF. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12071624.","journal-title":"Biomedicines"},{"key":"1739_CR113","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1111\/cas.14934","volume":"112","author":"KT Jin","year":"2021","unstructured":"Jin KT, Du WL, Lan HR, Liu YY, Mao CS, Du JL, et al. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: a comprehensive review. Cancer Sci. 2021;112:2592\u2013606.","journal-title":"Cancer Sci"},{"key":"1739_CR114","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1158\/1078-0432.CCR-19-2923","volume":"26","author":"E Bresnahan","year":"2020","unstructured":"Bresnahan E, Lindblad KE. Ruiz de Galarreta M, Lujambio A: Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clin Cancer Res. 2020;26:5276\u201386.","journal-title":"Clin Cancer Res"},{"key":"1739_CR115","doi-asserted-by":"publisher","unstructured":"Li E, Lin L, Chen CW, Ou DL. Mouse models for immunotherapy in hepatocellular carcinoma. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11111800.","DOI":"10.3390\/cancers11111800"},{"key":"1739_CR116","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ame2.12353","volume":"7","author":"H Yue","year":"2024","unstructured":"Yue H, Bai L. Progress, implications, and challenges in using humanized immune system mice in CAR-T therapy-application evaluation and improvement. Anim Model Exp Med. 2024;7:3\u201311.","journal-title":"Anim Model Exp Med"},{"key":"1739_CR117","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023;20:192\u2013206.","journal-title":"Nat Rev Clin Oncol"},{"key":"1739_CR118","doi-asserted-by":"publisher","unstructured":"Magre L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, Desai J. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006290.","DOI":"10.1136\/jitc-2022-006290"},{"key":"1739_CR119","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nbt.2858","volume":"32","author":"A Rongvaux","year":"2014","unstructured":"Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32:364\u201372.","journal-title":"Nat Biotechnol"},{"key":"1739_CR120","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41684-023-01196-z","volume":"52","author":"NM Del Rio","year":"2023","unstructured":"Del Rio NM, Huang L, Murphy L, Babu JS, Daffada CM, Haynes WJ, et al. Generation of the NeoThy mouse model for human immune system studies. Lab Anim. 2023;52:149\u201368.","journal-title":"Lab Anim"},{"key":"1739_CR121","doi-asserted-by":"publisher","first-page":"e70065","DOI":"10.1111\/liv.70065","volume":"45","author":"C Ramier","year":"2025","unstructured":"Ramier C, Protopopescu C, Di Beo V, Parlati L, Marcellin F, Carrat F, et al. Behaviour-based predictive scores of hepatocellular carcinoma in people with chronic hepatitis B (ANRS CO22 HEPATHER). Liver Int. 2025;45:e70065.","journal-title":"Liver Int"},{"key":"1739_CR122","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3449","volume":"13","author":"A Arzumanyan","year":"2013","unstructured":"Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123\u201335.","journal-title":"Nat Rev Cancer"},{"key":"1739_CR123","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000394","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Danilova L, Lim SJ, Verma R, Xavier S, Leatherman JM, et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000394.","journal-title":"J Immunother Cancer"},{"key":"1739_CR124","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1739_CR125","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450\u20136.","journal-title":"Nature"},{"key":"1739_CR126","unstructured":"Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. beta-Catenin signaling in hepatocellular carcinoma. J Clin Invest. 22:32."},{"key":"1739_CR127","doi-asserted-by":"publisher","first-page":"107043","DOI":"10.1016\/j.intimp.2020.107043","volume":"89","author":"X Xiao","year":"2020","unstructured":"Xiao X, Mo H, Tu K. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression. Int Immunopharmacol. 2020;89:107043.","journal-title":"Int Immunopharmacol"},{"key":"1739_CR128","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M de Ruiz Galarreta","year":"2019","unstructured":"Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, et al: beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discov. 2019;9:1124\u20131141.","journal-title":"Cancer Discov"},{"key":"1739_CR129","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1136\/gutjnl-2023-331342","volume":"73","author":"N Cai","year":"2024","unstructured":"Cai N, Cheng K, Ma Y, Liu S, Tao R, Li Y, et al. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8(+) T cell-mediated antitumour immunity and improves anti-PD-1 efficacy. Gut. 2024;73:985\u201399.","journal-title":"Gut"},{"key":"1739_CR130","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330.","journal-title":"Nature"},{"key":"1739_CR131","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jcmgh.2019.08.004","volume":"9","author":"D Di Blasi","year":"2020","unstructured":"Di Blasi D, Boldanova T, Mori L, Terracciano L, Heim MH, De Libero G. Unique T-cell populations define immune-inflamed hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2020;9:195\u2013218.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1739_CR132","doi-asserted-by":"publisher","first-page":"1326097","DOI":"10.3389\/fimmu.2023.1326097","volume":"14","author":"R Qin","year":"2023","unstructured":"Qin R, Jin T, Xu F. Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma. Front Immunol. 2023;14:1326097.","journal-title":"Front Immunol"},{"key":"1739_CR133","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1007\/s00432-022-04201-z","volume":"149","author":"J Liu","year":"2023","unstructured":"Liu J, Ma J, Xing N, Ji Z, Li J, Zhang S, et al. Interferon-gamma predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. J Cancer Res Clin Oncol. 2023;149:3043\u201350.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1739_CR134","doi-asserted-by":"publisher","first-page":"890019","DOI":"10.3389\/fimmu.2022.890019","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Li S, Wu B, Xu Q, Teng D, Yang T, et al. Landscape of immune cells heterogeneity in liver transplantation by single-cell RNA sequencing analysis. Front Immunol. 2022;13:890019.","journal-title":"Front Immunol"},{"key":"1739_CR135","doi-asserted-by":"publisher","first-page":"167120","DOI":"10.1016\/j.bbadis.2024.167120","volume":"1870","author":"S Chakraborty","year":"2024","unstructured":"Chakraborty S, Sharma G, Karmakar S, Banerjee S. Multi-OMICS approaches in cancer biology: new era in cancer therapy. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167120.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1739_CR136","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.7150\/thno.71873","volume":"12","author":"YF Wang","year":"2022","unstructured":"Wang YF, Yuan SX, Jiang H, Li ZX, Yin HZ, Tan J, et al. Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment. Theranostics. 2022;12:4163\u201380.","journal-title":"Theranostics"},{"key":"1739_CR137","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41698-024-00752-1","volume":"8","author":"J Ye","year":"2024","unstructured":"Ye J, Lin Y, Liao Z, Gao X, Lu C, Lu L, et al. Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma. NPJ Precis Oncol. 2024;8:262.","journal-title":"NPJ Precis Oncol"},{"key":"1739_CR138","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3892\/or.2017.5722","volume":"38","author":"J Liu","year":"2017","unstructured":"Liu J, Liu Y, Meng L, Liu K, Ji B. Targeting the PD-L1\/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep. 2017;38:899\u2013907.","journal-title":"Oncol Rep"},{"key":"1739_CR139","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"1739_CR140","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.21037\/tcr-20-3415","volume":"10","author":"Z Yang","year":"2021","unstructured":"Yang Z, Zhang L, Liu J, Yang L, Xue H, Bai S, et al. PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma. Transl Cancer Res. 2021;10:2305\u201317.","journal-title":"Transl Cancer Res"},{"key":"1739_CR141","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3727\/096504016X14809827856524","volume":"25","author":"X Jin","year":"2017","unstructured":"Jin X, Tian S, Li P. Histone acetyltransferase 1 promotes cell proliferation and induces cisplatin resistance in hepatocellular carcinoma. Oncol Res. 2017;25:939\u201346.","journal-title":"Oncol Res"},{"key":"1739_CR142","doi-asserted-by":"publisher","first-page":"8216541","DOI":"10.1155\/2020\/8216541","volume":"2020","author":"Y Wang","year":"2020","unstructured":"Wang Y, Yang L, Dong X, Yang X, Zhang X, Liu Z, et al. Overexpression of NNT-AS1 Activates TGF-beta Signaling to Decrease Tumor CD4 Lymphocyte Infiltration in Hepatocellular Carcinoma. Biomed Res Int. 2020;2020:8216541.","journal-title":"Biomed Res Int"},{"key":"1739_CR143","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12943-024-01988-y","volume":"23","author":"YT Chan","year":"2024","unstructured":"Chan YT, Wu J, Lu Y, Li Q, Feng Z, Xu L, et al. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. Mol Cancer. 2024;23:74.","journal-title":"Mol Cancer"},{"key":"1739_CR144","doi-asserted-by":"publisher","first-page":"976196","DOI":"10.3389\/fimmu.2022.976196","volume":"13","author":"SMP Vadevoo","year":"2022","unstructured":"Vadevoo SMP, Gunassekaran GR, Yoo JD, Kwon TH, Hur K, Chae S, et al. Epigenetic therapy reprograms M2-type tumor-associated macrophages into an M1-like phenotype by upregulating miR-7083-5p. Front Immunol. 2022;13:976196.","journal-title":"Front Immunol"},{"key":"1739_CR145","doi-asserted-by":"publisher","unstructured":"Yang W, Feng Y, Zhou J, Cheung OK, Cao J, Wang J, et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.aaz6804.","DOI":"10.1126\/scitranslmed.aaz6804"},{"key":"1739_CR146","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00262-018-2283-0","volume":"68","author":"D Llopiz","year":"2019","unstructured":"Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother. 2019;68:379\u201393.","journal-title":"Cancer Immunol Immunother"},{"key":"1739_CR147","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1136\/gutjnl-2024-332281","volume":"74","author":"Y Tu","year":"2025","unstructured":"Tu Y, Wu H, Zhong C, Liu Y, Xiong Z, Chen S, et al. Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma. Gut. 2025;74:613\u201327.","journal-title":"Gut"},{"key":"1739_CR148","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","volume":"7","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019;7:193.","journal-title":"J Immunother Cancer"},{"key":"1739_CR149","doi-asserted-by":"publisher","first-page":"101900","DOI":"10.1016\/j.xcrm.2024.101900","volume":"6","author":"XQ Wu","year":"2025","unstructured":"Wu XQ, Ying F, Chung KPS, Leung CON, Leung RWH, So KKH, et al. Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma. Cell Rep Med. 2025;6:101900.","journal-title":"Cell Rep Med"},{"key":"1739_CR150","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12964-023-01219-9","volume":"21","author":"D Zhang","year":"2023","unstructured":"Zhang D, Jian YP, Zhang YN, Li Y, Gu LT, Sun HH, et al. Short-chain fatty acids in diseases. Cell Commun Signal. 2023;21:212.","journal-title":"Cell Commun Signal"},{"key":"1739_CR151","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1186\/s12967-024-05709-3","volume":"22","author":"C Liu","year":"2024","unstructured":"Liu C, Fu L, Wang Y, Yang W. Influence of the gut microbiota on immune cell interactions and cancer treatment. J Transl Med. 2024;22:939.","journal-title":"J Transl Med"},{"key":"1739_CR152","doi-asserted-by":"publisher","unstructured":"He Y, Huang J, Li Q, Xia W, Zhang C, Liu Z, et al. Gut microbiota and tumor immune escape: a new perspective for improving tumor immunotherapy. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14215317.","DOI":"10.3390\/cancers14215317"},{"key":"1739_CR153","doi-asserted-by":"publisher","first-page":"1030745","DOI":"10.3389\/fimmu.2022.1030745","volume":"13","author":"X Hou","year":"2022","unstructured":"Hou X, Zheng Z, Wei J, Zhao L. Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer. Front Immunol. 2022;13:1030745.","journal-title":"Front Immunol"},{"key":"1739_CR154","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","volume":"5","author":"DJ Pinato","year":"2019","unstructured":"Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5:1774\u20138.","journal-title":"JAMA Oncol"},{"key":"1739_CR155","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595\u2013602.","journal-title":"Science"},{"issue":"1380\u20131393","key":"1739_CR156","first-page":"e1389","volume":"32","author":"Y Kim","year":"2024","unstructured":"Kim Y, Kim G, Kim S, Cho B, Kim SY, Do EJ, et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe. 2024;32(1380\u20131393):e1389.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"1739_CR157","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41392-019-0074-5","volume":"4","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Tang H, Chen P, Xie H, Tao Y. Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduct Target Ther. 2019;4(1):41.","journal-title":"Signal Transduct Target Ther"},{"key":"1739_CR158","doi-asserted-by":"crossref","unstructured":"Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH: Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2022-004779"},{"key":"1739_CR159","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1038\/s41467-022-31141-6","volume":"13","author":"Y Shen","year":"2022","unstructured":"Shen Y, Lu C, Song Z, Qiao C, Wang J, Chen J, et al. Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-beta degradation. Nat Commun. 2022;13:3419.","journal-title":"Nat Commun"},{"key":"1739_CR160","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.annonc.2023.02.011","volume":"34","author":"A Spreafico","year":"2023","unstructured":"Spreafico A, Heirali AA, Araujo DV, Tan TJ, Oliva M, Schneeberger PHH, et al. First-in-class microbial ecosystem therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Ann Oncol. 2023;34:520\u201330.","journal-title":"Ann Oncol"},{"issue":"4355\u20134372","key":"1739_CR161","first-page":"e4322","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, Liu C, et al. LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity. Cell. 2024;187(4355\u20134372):e4322.","journal-title":"Cell"},{"key":"1739_CR162","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24\u201334.","journal-title":"N Engl J Med"},{"key":"1739_CR163","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-018-0667-4","volume":"11","author":"F Liu","year":"2018","unstructured":"Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma. J Hematol Oncol. 2018;11:126.","journal-title":"J Hematol Oncol"},{"key":"1739_CR164","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, Tian W, Wang Z, Zhang J, Zhou R. Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer. 2023;22:93.","journal-title":"Mol Cancer"},{"key":"1739_CR165","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1038\/s12276-024-01336-6","volume":"56","author":"RJ Zhang","year":"2024","unstructured":"Zhang RJ, Kim TK. VISTA-mediated immune evasion in cancer. Exp Mol Med. 2024;56:2348\u201356.","journal-title":"Exp Mol Med"},{"key":"1739_CR166","doi-asserted-by":"crossref","unstructured":"Gonzalez-Sanchez E, Vaquero J, Fernandez-Barrena MG, Lasarte JJ, Avila MA, Sarobe P, Reig M, Calvo M, Fabregat I: The TGF-beta Pathway: A Pharmacological Target in Hepatocellular Carcinoma? Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13133248"},{"key":"1739_CR167","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.molmed.2019.06.007","volume":"25","author":"J Chen","year":"2019","unstructured":"Chen J, Gingold JA, Su X. Immunomodulatory TGF-beta signaling in hepatocellular carcinoma. Trends Mol Med. 2019;25:1010\u201323.","journal-title":"Trends Mol Med"},{"key":"1739_CR168","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40425-018-0356-4","volume":"6","author":"RB Holmgaard","year":"2018","unstructured":"Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, et al. Targeting the TGFbeta pathway with galunisertib, a TGFbetaRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer. 2018;6:47.","journal-title":"J Immunother Cancer"},{"key":"1739_CR169","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13046-019-1420-8","volume":"38","author":"C D\u2019Alterio","year":"2019","unstructured":"D\u2019Alterio C, Buoncervello M, Ierano C, Napolitano M, Portella L, Rea G, et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. J Exp Clin Cancer Res. 2019;38:432.","journal-title":"J Exp Clin Cancer Res"},{"key":"1739_CR170","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2326-6066.CIR-24-0324","volume":"13","author":"S Morita","year":"2025","unstructured":"Morita S, Lei PJ, Shigeta K, Ando T, Kobayashi T, Kikuchi H, et al. Combination CXCR4 and PD-1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma. Cancer Immunol Res. 2025;13:162\u201370.","journal-title":"Cancer Immunol Res"},{"key":"1739_CR171","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13046-017-0533-1","volume":"36","author":"M Wang","year":"2017","unstructured":"Wang M, Zhao X, Zhu D, Liu T, Liang X, Liu F, et al. HIF-1alpha promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J Exp Clin Cancer Res. 2017;36:60.","journal-title":"J Exp Clin Cancer Res"},{"key":"1739_CR172","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/hep.27320","volume":"60","author":"CC Wong","year":"2014","unstructured":"Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Lai RK, et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology. 2014;60:1645\u201358.","journal-title":"Hepatology"},{"key":"1739_CR173","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.31236","volume":"72","author":"W Chen","year":"2020","unstructured":"Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H. Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis. Hepatology. 2020;72:729\u201341.","journal-title":"Hepatology"},{"key":"1739_CR174","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.18632\/oncotarget.26998","volume":"10","author":"C Ang","year":"2019","unstructured":"Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019;10:4018\u201325.","journal-title":"Oncotarget"},{"key":"1739_CR175","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500\u20131.","journal-title":"N Engl J Med"},{"key":"1739_CR176","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-19-0558","volume":"25","author":"L Liu","year":"2019","unstructured":"Liu L, Bai X, Wang J, Tang XR, Wu DH, Du SS, et al. Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer. Clin Cancer Res. 2019;25:7413\u201323.","journal-title":"Clin Cancer Res"},{"key":"1739_CR177","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3892\/ol.2023.13845","volume":"25","author":"A Kuwano","year":"2023","unstructured":"Kuwano A, Yada M, Miyazaki Y, Tanaka K, Kurosaka K, Ohishi Y, et al. Tumor-infiltrating CD8(+) T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma. Oncol Lett. 2023;25:259.","journal-title":"Oncol Lett"},{"key":"1739_CR178","doi-asserted-by":"crossref","unstructured":"Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, et al: The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers (Basel). 2023;15.","DOI":"10.20944\/preprints202309.0857.v1"},{"key":"1739_CR179","doi-asserted-by":"publisher","unstructured":"Saleh R, Toor SM, Khalaf S, Elkord E. Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4(+) T cells. Vaccines (Basel). 2019. https:\/\/doi.org\/10.3390\/vaccines7040149.","DOI":"10.3390\/vaccines7040149"},{"key":"1739_CR180","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.ijbiomac.2022.09.129","volume":"221","author":"S Vimalraj","year":"2022","unstructured":"Vimalraj S. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. Int J Biol Macromol. 2022;221:1428\u201338.","journal-title":"Int J Biol Macromol"},{"key":"1739_CR181","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051056","author":"C Schiliro","year":"2021","unstructured":"Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10051056.","journal-title":"Cells"},{"key":"1739_CR182","doi-asserted-by":"publisher","first-page":"100443","DOI":"10.1016\/j.jhepr.2022.100443","volume":"4","author":"D Nam","year":"2022","unstructured":"Nam D, Chapiro J, Paradis V, Seraphin TP, Kather JN. Artificial intelligence in liver diseases: improving diagnostics, prognostics and response prediction. JHEP Rep. 2022;4:100443.","journal-title":"JHEP Rep"},{"key":"1739_CR183","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1186\/s12967-024-05613-w","volume":"22","author":"W Tong","year":"2024","unstructured":"Tong W, Wang T, Bai Y, Yang X, Han P, Zhu L, et al. Spatial transcriptomics reveals tumor-derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment. J Transl Med. 2024;22:840.","journal-title":"J Transl Med"},{"key":"1739_CR184","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","volume":"9","author":"T Yau","year":"2024","unstructured":"Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:310\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1739_CR185","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1739_CR186","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1158\/1538-7445.AM2018-4349","volume":"78","author":"X Tang","year":"2018","unstructured":"Tang X, Fan L, Chen G, Guo W, Qiu F, Wang J, et al. Abstract 4349: higher level of tumor mutational burden and 11q13 amplification in Chinese hepatocellular carcinoma patients. Cancer Res. 2018;78:4349\u20134349.","journal-title":"Cancer Res"},{"issue":"1","key":"1739_CR187","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/liv.14706","volume":"41","author":"CN Wong","year":"2021","unstructured":"Wong CN, Fessas P, Dominy K, Mauri FA, Kaneko T, Parcq PD, et al. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int. 2021;41(1):192\u2013203.","journal-title":"Liver Int"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01739-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01739-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01739-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:02:48Z","timestamp":1758884568000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01739-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":187,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1739"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01739-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}